Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Ther Deliv. 2015 Jul;6(7):795–826. doi: 10.4155/tde.15.34

Figure 7. Strategies for targeting red blood cells via CR1.

Figure 7

(A) RBCs can be used to clear immune complexes by way of the interaction between complement protein C3b and CR1. (B) Bispecific antibodies to CR1 and pathogens can be used to capture pathogens via the RBC surface. (C) Antibody/drug fusions targeted to CR1 can be used to attach therapeutic moieties directly to the RBC surface.

RES: Reticuloendothelial system.